Comparison of botulinum toxins A and B in the aesthetic treatment of facial rhytides

Dermatologic Surgery

Volumn 29, Issue 4, 2003, Pages 340-347

  Sadick, Neil S ^a,b   Herman, Alysa R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DYSTONIA; ESTHETICS; FACE DEFORMITY; FACE MUSCLE; HUMAN; INTERMETHOD COMPARISON; MOLECULAR SIZE; MUSCLE WEAKNESS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIGEN-ANTIBODY REACTIONS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; CHEMISTRY, PHARMACEUTICAL; HUMANS; RHYTIDOPLASTY;

EID: 0037387030     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2003.29082.x     Document Type: Article

References (44)

1. Pierard GE, Lapiere CM. The microanatomical basis of facial frown lines. Arch Dermatol 1989;125:1090-2.
2. Wider J, Moy R. Understanding botulinum toxin, surgery anatomy of the frown, forehead, and periocular region. Dermatol Surg 1998;24:1172-4.
3. Driezen NG, Framm L. Sudden unilateral visual loss after autologous fat injection into the glabellar area. Am J Ophthalmol 1989;107:85-6.
4. Stegman SJ, Chu S, Armstrong R. Adverse reactions to bovine collagen implant: clinical and histologic features. J Dermatol Surg Oncol 1988;13 (Suppl 1):39.
5. Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with C botulinum-A exotoxin. J Dermatol Surg Oncol 1992;18:17-21.
6. Blitzer A, Brin MF, Keen MF, et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993;119:1018-22.
7. Guyuron B, Huddleston SW. Aesthetic indications for botulinum toxin injection. Plast Reconstr Surg 1994;93:913-8.
8. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind placebo-controlled study. Plast Reconstr Surg 1994;94:94-9.
9. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of Neurobloc™ (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-46.
10. Brin M, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc™ (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-8.
11. Kessler KR, Benecke R. Botulinum toxin: from poison to remedy. Neurotoxicology 1997;18:761-70.
12. Lamanna C. The most poisonous poison. Science 1969;130:763-72.
13. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon. JAMA 2001;285:1059-70.
14. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther 1983;19:165-94.
15. Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg 2001;20:127-36.
16. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 1986;26:427-53.
17. Oguma K, Fujinaga Y, Inoue K. Structure and function of Clostridium botulinum toxins. Microbiol Immunol 1995;39:161-8.
18. Olney RK, Aminoff MJ, Gelb DJ, Lowenstein DH. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988;38:1780-3.
19. Fagien S, Brandt FS. Primary and adjunctive use of botulinum toxin type A (Botox) in facial aesthetic surgery. Clin Plast Surg 2001;28:127-48.
20. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000;55 (Suppl 5):S23-8.
21. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A patients with torticollis. Mov Disord 1994;9:213-7.
22. Jankovic J, Schwartz KS. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-6.
23. Zuber M, Sebald M, Bathien N, et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-8.
24. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.
25. Hexsel DM, de Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted in 6 consecutive weeks. Dermatol Surg, in press.
26. Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol 1996;35:569-72.
27. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46:840-9.
28. Blitzer A, Binder W, Aviv J, et al. The management of hyperfunctional facial lines with botulinum toxin: a collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997;123:389-92.
29. Brandt F, Bellman B. Cosmetic uses of botulinum A exotoxin for the aging neck. Dermatol Surg 1998;24:1232-4.
30. Carucci J. Botulinum exotoxin A for rejuvenation of the upper third of the face. Facial Plast Surg 2001;17:11-20.
31. Carruthers J, Carruthers A. Botox use in the mid and lower face and neck. Semin Cutan Med Surg 2001;20:85-92.
32. Foster J, Barnhorst D, Papay F, Oh P, Wulc A. The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology 1996;103:618-22.
33. Flynn T, Carruthers J, Carruthers A. Botulinum A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 2001;27:703-8.
34. Hankins C, Strimling R, Rogers G. Botulinum A toxin for glabellar wrinkles, dose and response. Dermatol Surg 1998;24:1181-3.
35. Huilgol S, Carruthers A, Carruthers J. Raising eyebrows with botulinum toxin. Dermatol Surg 1999;25:373-6.
36. Matarasso A. Botulinum A exotoxin for the management of platysmal bands. Plast Reconstr Surg 1999;103:645-52.
37. West T, Alster T. Effect of botulinum toxin type A on movement-associated rhytides following CO2 laser resurfacing. Dermatol Surg 1999;25:260-1.
38. Carruthers A, Carruthers JDA. The use of botulinum toxin to treat glabellar frown lines and other facial wrinkles. Cosmet Dermatol 1994;7:11-5.
39. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (Myobloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 2002;126:459-67.
40. Lowe NJ, Yamauchi PS, Lask GP, et al. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002;4:15-8.
41. Sadick NS. Botulinum toxin type B (Myobloc) for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 2002;29:817-21.
42. Sadick NS. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 units for the treatment of glabellar wrinkles. Dermatol Surg, in press.
43. Spencer JM, Gordon M, Goldberg DJ. Botulinum B treatment of the glabellar and frontalis regions: a dose-response analysis. J Cosmet Laser Ther 2002;4:19-23.
44. Glogau RG. A review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. Clin J Pain, in press.